Next Article in Journal
Antibodies against Platelet Factor 4 and Their Associated Pathologies: From HIT/HITT to Spontaneous HIT-Like Syndrome, to COVID-19, to VITT/TTS
Next Article in Special Issue
Ramifications of the HLA-I Allelic Reactivity of Anti-HLA-E*01:01 and Anti-HLA-E*01:03 Heavy Chain Monoclonal Antibodies in Comparison with Anti-HLA-I IgG Reactivity in Non-Alloimmunized Males, Melanoma-Vaccine Recipients, and End-Stage Renal Disease Patients
Previous Article in Journal
New Opportunities in Glycan Engineering for Therapeutic Proteins
Previous Article in Special Issue
Pharmacokinetic Developability and Disposition Profiles of Bispecific Antibodies: A Case Study with Two Molecules
 
 
Article

Article Versions Notes

Antibodies 2022, 11(1), 6; https://doi.org/10.3390/antib11010006
Action Date Notes Link
article xml file uploaded 13 January 2022 09:40 CET Original file -
article xml uploaded. 13 January 2022 09:40 CET Update -
article pdf uploaded. 13 January 2022 09:41 CET Version of Record -
article supplementary file uploaded. 13 January 2022 09:41 CET - https://www.mdpi.com/2073-4468/11/1/6#supplementary
article html file updated 13 January 2022 09:42 CET Original file -
article xml file uploaded 13 January 2022 10:18 CET Update -
article xml uploaded. 13 January 2022 10:18 CET Update https://www.mdpi.com/2073-4468/11/1/6/xml
article pdf uploaded. 13 January 2022 10:18 CET Updated version of record https://www.mdpi.com/2073-4468/11/1/6/pdf
article html file updated 13 January 2022 10:19 CET Update -
article html file updated 31 July 2022 03:32 CEST Update https://www.mdpi.com/2073-4468/11/1/6/html
Back to TopTop